http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106831594-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-50 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-50 |
| filingDate | 2017-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106831594-B |
| titleOfInvention | Clonidine embonate and preparation method thereof |
| abstract | The present invention relates to clonidine embonate and preparation method thereof.The salt is clonidine and embonate with 2:1 mol ratio is formed in a solvent.Three kinds of crystal formations be present in clonidine embonate provided by the invention, its solubility is relatively low, solubility is about percent one (2.19mg/mls) of the 0.02mg/ml equivalent to clonidine in water, the one thousandth (79.4mg/ml) of clonidine hydrochloride, reach slow release effect without complicated preparation process can, and it is highly stable, do not occur to turn crystalline substance under hot and humid high light conditions and under the conditions of accelerated test；Manufacture craft is simple, and granularity is easily controlled, and is adapted to amplification production.The salt, which is adapted to make long-acting slow-release preparation, can reduce times for spraying, improve patient medication compliance, can balance blood concentration, avoid peak valley phenomenon, reduce bad kickback of using medicine. |
| priorityDate | 2017-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 49.